These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 36403026)

  • 21. Preclinical discovery and development of fingolimod for the treatment of multiple sclerosis.
    Volpi C; Orabona C; Macchiarulo A; Bianchi R; Puccetti P; Grohmann U
    Expert Opin Drug Discov; 2019 Nov; 14(11):1199-1212. PubMed ID: 31389262
    [No Abstract]   [Full Text] [Related]  

  • 22. Response to Fingolimod in Multiple Sclerosis Patients Is Associated with a Differential Transcriptomic Regulation.
    Sánchez-Sanz A; Muñoz-Viana R; Sabín-Muñoz J; Moreno-Torres I; Brea-Álvarez B; Rodríguez-De la Fuente O; García-Merino A; Sánchez-López AJ
    Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338652
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fingolimod inhibits brain atrophy and promotes brain-derived neurotrophic factor in an animal model of multiple sclerosis.
    Smith PA; Schmid C; Zurbruegg S; Jivkov M; Doelemeyer A; Theil D; Dubost V; Beckmann N
    J Neuroimmunol; 2018 May; 318():103-113. PubMed ID: 29530550
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Beneficial effects of fingolimod in MS patients with high serum Sema4A levels.
    Koda T; Namba A; Nakatsuji Y; Niino M; Miyazaki Y; Sugimoto T; Kinoshita M; Takata K; Yamashita K; Shimizu M; Fukazawa T; Kumanogoh A; Mochizuki H; Okuno T
    PLoS One; 2018; 13(3):e0193986. PubMed ID: 29518148
    [TBL] [Abstract][Full Text] [Related]  

  • 25. S1P(1) receptor modulation with cyclical recovery from lymphopenia ameliorates mouse model of multiple sclerosis.
    Gonzalez-Cabrera PJ; Cahalan SM; Nguyen N; Sarkisyan G; Leaf NB; Cameron MD; Kago T; Rosen H
    Mol Pharmacol; 2012 Feb; 81(2):166-74. PubMed ID: 22031473
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Frontline Science: Induction of experimental autoimmune encephalomyelitis mobilizes Th17-promoting myeloid derived suppressor cells to the lung.
    Glenn JD; Liu C; Whartenby KA
    J Leukoc Biol; 2019 May; 105(5):829-841. PubMed ID: 30762897
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bruton's tyrosine kinase inhibition reduces disease severity in a model of secondary progressive autoimmune demyelination.
    Evonuk KS; Wang S; Mattie J; Cracchiolo CJ; Mager R; Ferenčić Ž; Sprague E; Carrier B; Schofield K; Martinez E; Stewart Z; Petrosino T; Johnson GA; Yusuf I; Plaisted W; Naiman Z; Delp T; Carter L; Marušić S
    Acta Neuropathol Commun; 2023 Jul; 11(1):115. PubMed ID: 37438842
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Methylprednisolone alleviates multiple sclerosis by expanding myeloid-derived suppressor cells via glucocorticoid receptor β and S100A8/9 up-regulation.
    Wang Z; Zheng G; Li G; Wang M; Ma Z; Li H; Wang XY; Yi H
    J Cell Mol Med; 2020 Dec; 24(23):13703-13714. PubMed ID: 33094923
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting synaptic pathology in multiple sclerosis: fingolimod to the rescue?
    Gillingwater TH
    Br J Pharmacol; 2012 Feb; 165(4):858-60. PubMed ID: 21806598
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fingolimod attenuates gait deficits in mice subjected to experimental autoimmune encephalomyelitis.
    Kasheke GDS; Holman SP; Robertson GS
    J Neuroimmunol; 2022 Sep; 370():577926. PubMed ID: 35863299
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of EAE mice with Treg, G-MDSC and IL-2: a new insight into cell therapy for multiple sclerosis.
    Ghorbani MM; Farazmandfar T; Abediankenari S; Hassannia H; Maleki Z; Shahbazi M
    Immunotherapy; 2022 Jul; 14(10):789-798. PubMed ID: 35678041
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation.
    Choi JW; Gardell SE; Herr DR; Rivera R; Lee CW; Noguchi K; Teo ST; Yung YC; Lu M; Kennedy G; Chun J
    Proc Natl Acad Sci U S A; 2011 Jan; 108(2):751-6. PubMed ID: 21177428
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Circulating Myeloid-Derived Suppressor Cell Subsets in Patients with Colorectal Cancer - Exploratory Analysis of Their Biomarker Potential.
    Fědorová L; Pilátová K; Selingerová I; Bencsiková B; Budinská E; Zwinsová B; Brychtová V; Langrová M; Šefr R; Valík D; Zdražilová Dubská L
    Klin Onkol; 2018; 31(Suppl 2):88-92. PubMed ID: 31023030
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Type I IFN signaling in T regulatory cells modulates chemokine production and myeloid derived suppressor cells trafficking during EAE.
    Tanwar S; Oguz C; Metidji A; Dahlstrom E; Barbian K; Kanakabandi K; Sykora L; Shevach EM
    J Autoimmun; 2020 Dec; 115():102525. PubMed ID: 32709481
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis.
    Cohen JA; Chun J
    Ann Neurol; 2011 May; 69(5):759-77. PubMed ID: 21520239
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diffusion tensor imaging detects treatment effects of FTY720 in experimental autoimmune encephalomyelitis mice.
    Wang X; Brieland JK; Kim JH; Chen YJ; O'Neal J; O'Neil SP; Tu TW; Trinkaus K; Song SK
    NMR Biomed; 2013 Dec; 26(12):1742-50. PubMed ID: 23939596
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fingolimod reduces circulating tight-junction protein levels and in vitro peripheral blood mononuclear cells migration in multiple sclerosis patients.
    Annunziata P; Cioni C; Masi G; Tassi M; Marotta G; Severi S
    Sci Rep; 2018 Oct; 8(1):15371. PubMed ID: 30337577
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vivo PET imaging demonstrates diminished microglial activation after fingolimod treatment in an animal model of multiple sclerosis.
    Airas L; Dickens AM; Elo P; Marjamäki P; Johansson J; Eskola O; Jones PA; Trigg W; Solin O; Haaparanta-Solin M; Anthony DC; Rinne J
    J Nucl Med; 2015 Feb; 56(2):305-10. PubMed ID: 25572093
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Monocytic myeloid-derived suppressor cells as an immune indicator of early diagnosis and prognosis in patients with sepsis.
    Cui J; Cai W; Lin J; Zhang L; Miao Y; Xu Y; Zhao W
    BMC Infect Dis; 2024 Apr; 24(1):399. PubMed ID: 38609858
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The mitochondriogenic but not the immunosuppressant effects of mTOR inhibitors prompt neuroprotection and delay disease evolution in a mouse model of progressive multiple sclerosis.
    Buonvicino D; Pratesi S; Ranieri G; Pistolesi A; Guasti D; Chiarugi A
    Neurobiol Dis; 2024 Feb; 191():106387. PubMed ID: 38142841
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.